This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Ranked Momentum Stocks to Buy for May 10th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 10th:
Teladoc (TDOC) Q1 Loss Lower Than Expected, '17 View Intact
by Zacks Equity Research
Teladoc Inc.'s (TDOC) operating loss of 30 cents per share came in narrower than the Zacks Consensus Estimate of a loss of 33 cents per share.
Cigna (CI) Beats on Q1 Earnings and Revenues, Guides Up
by Zacks Equity Research
Cigna (CI) earnings of $2.77 per share, comfortably beating the Zacks Consensus Estimate of $2.44.
Molina Healthcare (MOH) Q4 Earnings, Revenues Beat Estimates
by Zacks Equity Research
Molina Healthcare Inc. (MOH) reported first-quarter 2017 adjusted net income per share of $1.47 that surpassed the Zacks Consensus Estimate of 57 cents by 157%.
Stock Market News for May 05, 2017
by Zacks Equity Research
Benchmarks mostly ended flat on Thursday amid drop in oil prices and the first steps taken by House Republicans to repeal Obamacare
Trumpcare Gets House Support: What Next?
by Arpita Dutt
Although the House of Representatives voted to repeal Obamacare, will the Senate vote for Trumpcare in its current form?
Company News for May 04, 2017
by Zacks Equity Research
Companies in the News are: YUM,CLX,RAI,HUM
Humana (HUM) Beats on Earnings, Misses Revenues in Q1
by Zacks Equity Research
Humana Inc.'s (HUM) first-quarter 2017 operating earnings per share of $2.75 beat the Zacks Consensus Estimate by approximately 8%.
Humana's (HUM) Q1 Earnings Beat, Revenues Miss
by Anupama Mukhopadhyay
Humana (HUM) surpassed our earnings estimate. Our consensus called for EPS of $2.55, and the company reported EPS of $2.75.
Is a Surprise Coming for Humana (HUM) This Earnings Season?
by Zacks Equity Research
Humana (HUM) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Aetna (AET) Tops Q1 Earnings; Revenues Miss, Down Y/Y
by Zacks Equity Research
Aetna beats on earnings. Our consensus called for EPS of $2.36 and the company reported earnings per share of $2.71 and increased 17% year over year
Can CVS Health (CVS) Spring a Surprise this Earnings Season?
by Zacks Equity Research
CVS Health Corporation (CVS) is scheduled to report its first-quarter 2017 results before the opening bell on May 2.
Universal Health (UHS) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Universal Health Services, Inc (UHS) is set to report first-quarter 2017 results on Apr 25, after the market closes.
Will Boston Scientific (BSX) Surprise this Earnings Season?
by Zacks Equity Research
Boston Scientific Corporation (BSX) is scheduled to report first-quarter 2017 results before the opening bell on Apr 27.
Will Thermo Fisher (TMO) Pull a Surprise in Q1 Earnings?
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) is scheduled to report first-quarter 2017 results before the opening bell on Apr 26.
What's in the Cards for Centene (CNC) this Earnings Season?
by Zacks Equity Research
Centene Corporation (CNC)will release first-quarter 2017 results on Apr 25, before the market opens.
Will Zimmer Biomet (ZBH) Beat Earnings Estimates in Q1?
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) is expected to beat earnings when it reports its first-quarter 2017 financial numbers on Apr 27.
Aetna (AET) Hurt by Exchange Business, High Medical Costs
by Zacks Equity Research
Shares of health insurer Aetna Inc. (AET) underperformed over the past one year.
Medicare Rates Rise More Than Expected, Insurers Breathe Easy
by Zacks Equity Research
The CMS has decided to raise 2018 Medicare Advantage more than expected.
Why Is Humana (HUM) Up 5.2% Since the Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Anthem (ANTM) About to Exit Public Exchange Business?
by Zacks Equity Research
Anthem Inc. (ANTM) is planning to scale back its participation on loss making public exchange business for 2018, as per analysts who met management.
Another Run at Health Care Reform: Impact on Healthcare
by Zacks Equity Research
We wait to see how "repealing and replacing" the Obamacare with ACHC proceeds.
ETFs Deserving a Close Watch If Health Care Plans Fail
by Sanghamitra Saha
With Trump's Health Care plans, due for voting today, these ETFs may see considerable movement.
Humana Poised to Grow on Government Business, Strong Capital
by Zacks Equity Research
Humana, Inc. (HUM) stock has long been an investor favorite owing to its strong fundamentals.
Humana's Subsidiaries Receive Rating Action from A.M. Best
by Zacks Equity Research
Humana Inc. (HUM) recently received rating action from A.M. Best. The rating giant has removed from under review, with positive implications, the majority of insurance subsidiaries of the company.